Small cell lung cancer.
暂无分享,去创建一个
A. Adjei | G. Dy | Alex A Adjei | T. Sher | Grace K Dy | Taimur Sher
[1] R. Salgia,et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] G. Bepler,et al. Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer , 2006, Clinical Cancer Research.
[3] R. Hatlevoll,et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] S. Lowe,et al. Genetic analysis of chemoresistance in primary murine lymphomas , 2000, Nature Medicine.
[5] N. Brünner,et al. In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. , 1998, British Journal of Cancer.
[6] R. Pellegrino,et al. AIRWAY HYPERRESPONSIVENESS IN ASTHMA. AUTHORS' REPLY , 1999 .
[7] M. Hidalgo,et al. A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500) , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] G. Fountzilas,et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] P. Postmus,et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. , 1987, European journal of cancer & clinical oncology.
[10] V. Ninane,et al. Prognostic factors for patients with small cell lung carcinoma , 2000, Cancer.
[11] A. Schwartz,et al. Temporal trends in small cell lung cancer: Analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Tomoyuki Watanabe,et al. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs , 2004, Investigational New Drugs.
[13] J. Hainsworth,et al. Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[14] Lutz Edler,et al. Myeloperoxidase (MPO) genotype and lung cancer histologic types: The MPO −463 A allele is associated with reduced risk for small cell lung cancer in smokers , 2002, International journal of cancer.
[15] J. Machiels,et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] F. Khuri,et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] Ashokakumar M. Patel,et al. Paraneoplastic syndromes associated with lung cancer. , 1993, Mayo Clinic proceedings.
[18] Y. Kashiwazaki,et al. Antitumor Activities of a Novel 9‐Aminoanthracycline (SM‐5887) against Mouse Experimental Tumors and Human Tumor Xenografts , 1989, Japanese journal of cancer research : Gann.
[19] Tadashi Suzuki,et al. Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: Comparative study with doxorubicin , 2004, Investigational New Drugs.
[20] L. Blavier,et al. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression , 2006, Cancer and Metastasis Reviews.
[21] R. Salgia,et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. , 2003, Cancer research.
[22] S. Korsmeyer,et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.
[23] W. Travis,et al. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. , 1994, American journal of clinical pathology.
[24] P. Warde,et al. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] P. Kristjansen,et al. Detection of bone marrow relapse in patients with small cell carcinoma of the lung , 1986, Cancer.
[26] F. Oesch,et al. c‐erbB‐2 Expression in small‐cell lung cancer is associated with poor prognosis , 2001, International journal of cancer.
[27] A. Murgo,et al. Lactate dehydrogenase values and bone scans as predictors of bone marrow involvement in small-cell lung cancer. , 1987, Archives of internal medicine.
[28] Judah Folkman,et al. Thalidomide is an inhibitor of angiogenesis. , 1994 .
[29] G. Giaccone,et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Cox,et al. Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). , 1986, International journal of radiation oncology, biology, physics.
[31] L. Collette,et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. , 2007, The New England journal of medicine.
[32] A. Tolcher,et al. Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma , 2005 .
[33] Z. Kmietowicz. Women at double risk of small cell lung cancer , 1998 .
[34] M. Fukuoka,et al. EGFR mutation in gefitinib-responsive small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] A. Wozniak,et al. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit positive extensive-stage small cell lung cancer (ES SCLC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] N. Saijo,et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] A. Hackshaw,et al. A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC): PRS-04 , 2007 .
[38] D. Slamon,et al. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. , 1992, Oncogene.
[39] H. Poulsen,et al. Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. , 1992, Cancer research.
[40] D. Moore,et al. A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): A trial of the Eastern Cooperative Oncology Group , 2007 .
[41] S. Honsawek,et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[42] J. Gills,et al. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. , 2005, Cancer research.
[43] N. Hanna,et al. Small-cell lung cancer: state of the art. , 2002, Clinical lung cancer.
[44] A. Adjei,et al. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] F. Hofmann,et al. The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy , 2005, Clinical Cancer Research.
[46] K. Mori,et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.
[47] R. Simon,et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] Michael R. Green,et al. CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC) , 2007 .
[49] J P Pignon,et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. , 1999, The New England journal of medicine.
[50] S. Steinberg,et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] M. Higashiyama,et al. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. , 1995, Anticancer research.
[52] D. Lane,et al. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo , 2000, Oncogene.
[53] D. Fabbro,et al. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. , 1997, Journal of the National Cancer Institute.
[54] A. Adjei,et al. The Ras/Raf/MAPK pathway. , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[55] H. Hansen,et al. Prophylactic cranial irradiation in small cell lung cancer--an update. , 1995, Lung cancer.
[56] J. Verweij,et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] L. Campbell,et al. Hematological, biochemical and bone scan findings in patients with marrow carcinoma , 1991, Pathology.
[58] A. Coldman,et al. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] B. Johnson,et al. Farnesyl Transferase Inhibitors for Patients with Lung Cancer , 2004, Clinical Cancer Research.
[60] U. Galderisi,et al. Antisense oligonucleotides as therapeutic agents , 1999, Journal of cellular physiology.
[61] L. Ek,et al. A randomized phase III trial of irinotecan plus carboplatin versus etoposide plus carboplatin in patients with small cell lung cancer, extensive disease (SCLC-ED): IRIS-Study , 2007 .
[62] P. Andersen,et al. Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] R. Salgia,et al. Haptoglobin α-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in Small cell lung cancer , 2004 .
[64] R. Salgia,et al. Activated c‐Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer , 2002, Journal of cellular and molecular medicine.
[65] D. Dunlop,et al. Phase II study of imatinib in patients with small cell lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[66] T. Nakamura,et al. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. , 1993, British Journal of Cancer.
[67] M. Rosenfeld,et al. P/Q‐type voltage‐gated calcium channel antibodies in paraneoplastic disorders of the central nervous system , 1999, Muscle & nerve.
[68] J. Crowley,et al. Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327) , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[69] R. Komaki,et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.
[70] M. Ladanyi,et al. EGFR mutations in small-cell lung cancers in patients who have never smoked. , 2006, The New England journal of medicine.
[71] J. Jett,et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[72] M. Socinski,et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] Edward L Spitznagel,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] L. Kanz,et al. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up report. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[75] Y. Kashiwazaki,et al. Toxicological Aspects of a Novel 9‐Aminoanthracycline, SM‐5887 , 1989, Japanese journal of cancer research : Gann.
[76] John Calvin Reed,et al. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. , 1994, Antisense research and development.
[77] N. Hanna,et al. Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC) , 2005 .
[78] J. Minna,et al. Molecular genetics of small cell lung carcinoma. , 2001, Seminars in oncology.
[79] L. Seymour,et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] H. Dienemann,et al. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. , 2003, Pharmacogenetics.
[81] T. Kameya,et al. Expression of bcl‐2 oncogene protein is prevalent in small cell lung carcinomas , 1995, The Journal of pathology.
[82] J. Roth,et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. , 1994, Cancer research.
[83] G. Giaccone,et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. , 1994, Chest.
[84] M. Partridge,et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. , 1989, British Journal of Cancer.
[85] J. Crawford,et al. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] R. Salgia,et al. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion , 2007, British Journal of Cancer.
[87] K. Uematsu,et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] M. Rosenfeld,et al. Absence of HuD gene mutations in paraneoplastic small cell lung cancer tissue , 1998, Neurology.
[89] J. Pujol,et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] L. Einhorn,et al. Postchemotherapy resection of residual tumor in limited stage small cell lung cancer. , 1987, Chest.
[91] R. Arriagada,et al. Prophylactic cranial irradiation in small cell lung cancer. , 2003, Seminars in oncology.
[92] N. Choi,et al. Radiation dose escalation in limited-stage small-cell lung cancer. , 2003, International journal of radiation oncology, biology, physics.
[93] J P Pignon,et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. , 1993, The New England journal of medicine.
[94] J. Carmichael,et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] J P Pignon,et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. , 1992, The New England journal of medicine.
[96] S. Monfardini,et al. Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses. , 2007, The oncologist.
[97] Bharat B. Aggarwal,et al. Nuclear factor‐κB (nf‐κB) is frequently expressed in lung cancer and preneoplastic lesions , 2006 .
[98] A. Schwartz,et al. Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.
[99] D. Ihde,et al. Therapy of small cell lung cancer: a perspective on two decades of clinical research. , 1988, Seminars in oncology.
[100] N. Saijo,et al. Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124 , 2007 .
[101] T. Shibata,et al. Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung , 2007, Cancer science.
[102] A. Tolcher,et al. Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma , 2007 .
[103] A. Ullrich,et al. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[104] R. Clough,et al. Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. , 2003, International journal of radiation oncology, biology, physics.
[105] J. Hainsworth,et al. Pancoast's syndrome and small cell lung cancer. , 1982, Chest.
[106] Marshall W. Anderson,et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. , 2004, American journal of human genetics.
[107] Yonghua Hu,et al. Passive smoking, metabolic gene polymorphisms, and infant birth weight in a prospective cohort study of Chinese women. , 2007, American journal of epidemiology.
[108] N. Rosen,et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. , 1995, Cancer research.
[109] David A. Smith,et al. Pemetrexed (P) in relapsed small cell lung cancer (SCLC): Preliminary results of a phase II trial , 2007 .
[110] B. O'neill,et al. Cerebral toxicity in patients treated for small cell carcinoma of the lung. , 1999, Mayo Clinic proceedings.
[111] G. Giaccone,et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] C. Obasaju,et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] Is there ever a role for salvage operations in limited small-cell lung cancer? , 1991 .
[114] H. Brauch,et al. Involvement of the RAFI locus, at band 3p25, in the 3p deletion of small‐cell lung cancer , 1991, Genes, chromosomes & cancer.
[115] R. Stahel,et al. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. , 1998, British Journal of Cancer.
[116] G. Giaccone,et al. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] J. Minna,et al. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. , 1991, Oncogene.
[118] N. Choi,et al. Importance of radiation dose in achieving improved loco-regional tumor control in limited stage small-cell lung carcinoma: an update. , 1989, International journal of radiation oncology, biology, physics.
[119] D. Osoba,et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[120] R. Ginsberg,et al. Surgical treatment for limited small-cell lung cancer. The University of Toronto Lung Oncology Group experience. , 1991, The Journal of thoracic and cardiovascular surgery.
[121] O. Lipatov,et al. A phase II study of picoplatin (pico) as second-line therapy for patients (pts) with small cell lung cancer (SCLC) who have resistant or refractory disease or have relapsed within 180 days of completing first-line, platinum (plat)-containing chemotherapy , 2007 .
[122] M. Fukuoka,et al. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. , 2007, Lung cancer.
[123] P Chomy,et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. , 1995, Journal of the National Cancer Institute.
[124] G. Otterson,et al. Genetic etiology of lung cancer. , 1992, Oncology.
[125] Mountain Cf. Clinical biology of small cell carcinoma: relationship to surgical therapy. , 1978 .
[126] M. Muers,et al. Rising incidence of SCLC in young women , 1999, Thorax.
[127] J. Daurès,et al. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent , 2000, British Journal of Cancer.
[128] J. Jett,et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.